Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2021
Times Cited: 18
Times Cited: 18
Times Cited
Times Co-cited
Similarity
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
Emilie Sbidian, Anna Chaimani, Sivem Afach, Liz Doney, Corinna Dressler, Camille Hua, Canelle Mazaud, Céline Phan, Carolyn Hughes, Dru Riddle,[...]. Cochrane Database Syst Rev 2020
22
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
Richard G Langley, Boni E Elewski, Mark Lebwohl, Kristian Reich, Christopher E M Griffiths, Kim Papp, Lluís Puig, Hidemi Nakagawa, Lynda Spelman, Bárður Sigurgeirsson,[...]. N Engl J Med 2014
16
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
16
Bimekizumab versus Secukinumab in Plaque Psoriasis.
Kristian Reich, Richard B Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden,[...]. N Engl J Med 2021
Kristian Reich, Richard B Warren, Mark Lebwohl, Melinda Gooderham, Bruce Strober, Richard G Langley, Carle Paul, Dirk De Cuyper, Veerle Vanvoorden, Cynthia Madden,[...]. N Engl J Med 2021
16
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, Ruquan You,[...]. J Am Acad Dermatol 2015
16
Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
K Reich, A Pinter, J P Lacour, C Ferrandiz, G Micali, L E French, M Lomaga, Y Dutronc, C Henneges, S Wilhelm,[...]. Br J Dermatol 2017
16
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada,[...]. Br J Dermatol 2020
A Blauvelt, K Papp, A Gottlieb, A Jarell, K Reich, C Maari, K B Gordon, L K Ferris, R G Langley, Y Tada,[...]. Br J Dermatol 2020
16
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
Mark Lebwohl, Bruce Strober, Alan Menter, Kenneth Gordon, Jolanta Weglowska, Lluis Puig, Kim Papp, Lynda Spelman, Darryl Toth, Francisco Kerdel,[...]. N Engl J Med 2015
16
Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE).
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
16
Etanercept as monotherapy in patients with psoriasis.
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
Craig L Leonardi, Jerold L Powers, Robert T Matheson, Bernard S Goffe, Ralph Zitnik, Andrea Wang, Alice B Gottlieb. N Engl J Med 2003
16
Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis.
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, Robert Sabat. Lancet 2021
Kamran Ghoreschi, Anna Balato, Charlotta Enerbäck, Robert Sabat. Lancet 2021
16
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
Neil H Shear, Keith A Betts, Ahmed M Soliman, Avani Joshi, Yan Wang, Jing Zhao, Paolo Gisondi, Ranjeeta Sinvhal, April W Armstrong. J Am Acad Dermatol 2021
40
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
Kristian Reich, Frank O Nestle, Kim Papp, Jean-Paul Ortonne, Robert Evans, Cynthia Guzzo, Shu Li, Lisa T Dooley, Christopher E M Griffiths. Lancet 2005
11
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Giao Do, Camille Hua, Canelle Mazaud, Catherine Droitcourt, Carolyn Hughes, John R Ingram, Luigi Naldi,[...]. Cochrane Database Syst Rev 2017
11
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.
R B Warren, A Blauvelt, Y Poulin, S Beeck, M Kelly, T Wu, Z Geng, C Paul. Br J Dermatol 2021
R B Warren, A Blauvelt, Y Poulin, S Beeck, M Kelly, T Wu, Z Geng, C Paul. Br J Dermatol 2021
11
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
Kenneth B Gordon, Andrew Blauvelt, Kim A Papp, Richard G Langley, Thomas Luger, Mamitaro Ohtsuki, Kristian Reich, David Amato, Susan G Ball, Daniel K Braun,[...]. N Engl J Med 2016
11
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
Christopher E M Griffiths, Kristian Reich, Mark Lebwohl, Peter van de Kerkhof, Carle Paul, Alan Menter, Gregory S Cameron, Janelle Erickson, Lu Zhang, Roberta J Secrest,[...]. Lancet 2015
11
Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review.
April W Armstrong, Charlotte Read. JAMA 2020
April W Armstrong, Charlotte Read. JAMA 2020
11
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Jerry Bagel, John Nia, Peter W Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi,[...]. Dermatol Ther (Heidelb) 2018
Jerry Bagel, John Nia, Peter W Hashim, Manmath Patekar, Ana de Vera, Sophie Hugot, Kuan Sheng, Summer Xia, Isabelle Gilloteau, Elisa Muscianisi,[...]. Dermatol Ther (Heidelb) 2018
11
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).
J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi,[...]. J Eur Acad Dermatol Venereol 2021
J Bagel, A Blauvelt, J Nia, P Hashim, M Patekar, A de Vera, K Ahmad, B Paguet, S Xia, E Muscianisi,[...]. J Eur Acad Dermatol Venereol 2021
13
Psoriasis prevalence among adults in the United States.
Tara D Rachakonda, Clayton W Schupp, April W Armstrong. J Am Acad Dermatol 2014
Tara D Rachakonda, Clayton W Schupp, April W Armstrong. J Am Acad Dermatol 2014
11
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
A Blauvelt, J C Prinz, A B Gottlieb, K Kingo, H Sofen, M Ruer-Mulard, V Singh, R Pathan, C Papavassilis, S Cooper. Br J Dermatol 2015
11
Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study).
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic,[...]. J Eur Acad Dermatol Venereol 2018
R Bissonnette, T Luger, D Thaçi, D Toth, A Lacombe, S Xia, R Mazur, M Patekar, P Charef, M Milutinovic,[...]. J Eur Acad Dermatol Venereol 2018
11
Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
Kristian Reich, Kim A Papp, Andrew Blauvelt, Richard G Langley, April Armstrong, Richard B Warren, Kenneth B Gordon, Joseph F Merola, Yukari Okubo, Cynthia Madden,[...]. Lancet 2021
11
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
Luís Puig, Andrey L Bakulev, Muza M Kokhan, Alexey V Samtsov, Vladislav R Khairutdinov, Maria A Morozova, Nikita A Zolkin, Ivan V Kuryshev, Alexey N Petrov, Antonina V Artemeva,[...]. Dermatol Ther (Heidelb) 2021
Luís Puig, Andrey L Bakulev, Muza M Kokhan, Alexey V Samtsov, Vladislav R Khairutdinov, Maria A Morozova, Nikita A Zolkin, Ivan V Kuryshev, Alexey N Petrov, Antonina V Artemeva,[...]. Dermatol Ther (Heidelb) 2021
100
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
Kenneth B Gordon, Peter Foley, James G Krueger, Andreas Pinter, Kristian Reich, Ronald Vender, Veerle Vanvoorden, Cynthia Madden, Katy White, Christopher Cioffi,[...]. Lancet 2021
11
Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study.
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
Carle Paul, Christopher E M Griffiths, Peter C M van de Kerkhof, Lluís Puig, Yves Dutronc, Carsten Henneges, Martin Dossenbach, Kristin Hollister, Kristian Reich. J Am Acad Dermatol 2019
11
A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.
A Blauvelt, C Leonardi, B Elewski, J J Crowley, L C Guenther, M Gooderham, R G Langley, R Vender, A Pinter, C E M Griffiths,[...]. Br J Dermatol 2021
A Blauvelt, C Leonardi, B Elewski, J J Crowley, L C Guenther, M Gooderham, R G Langley, R Vender, A Pinter, C E M Griffiths,[...]. Br J Dermatol 2021
11
A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
K A Papp, K Reich, C Paul, A Blauvelt, W Baran, C Bolduc, D Toth, R G Langley, J Cather, A B Gottlieb,[...]. Br J Dermatol 2016
11
Bimekizumab versus Adalimumab in Plaque Psoriasis.
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi,[...]. N Engl J Med 2021
Richard B Warren, Andrew Blauvelt, Jerry Bagel, Kim A Papp, Paul Yamauchi, April Armstrong, Richard G Langley, Veerle Vanvoorden, Dirk De Cuyper, Christopher Cioffi,[...]. N Engl J Med 2021
11
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
Andrew Blauvelt, Kristian Reich, Tsen-Fang Tsai, Stephen Tyring, Francisco Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Ronald Vender, Sophie Hugot,[...]. J Am Acad Dermatol 2017
11
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Sarfaraz A Hasni, Sarthak Gupta, Michael Davis, Elaine Poncio, Yenealem Temesgen-Oyelakin, Philip M Carlucci, Xinghao Wang, Mohammad Naqi, Martin P Playford, Rishi R Goel,[...]. Nat Commun 2021
Sarfaraz A Hasni, Sarthak Gupta, Michael Davis, Elaine Poncio, Yenealem Temesgen-Oyelakin, Philip M Carlucci, Xinghao Wang, Mohammad Naqi, Martin P Playford, Rishi R Goel,[...]. Nat Commun 2021
11
11
Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial.
M Lebwohl, K Papp, C Han, B Schenkel, N Yeilding, Y Wang, G G Krueger. Br J Dermatol 2010
M Lebwohl, K Papp, C Han, B Schenkel, N Yeilding, Y Wang, G G Krueger. Br J Dermatol 2010
11
Certolizumab pegol for the treatment of patients with moderate-to-severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials.
A Blauvelt, K Reich, M Lebwohl, D Burge, C Arendt, L Peterson, J Drew, R Rolleri, A B Gottlieb. J Eur Acad Dermatol Venereol 2019
A Blauvelt, K Reich, M Lebwohl, D Burge, C Arendt, L Peterson, J Drew, R Rolleri, A B Gottlieb. J Eur Acad Dermatol Venereol 2019
11
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
David Moher, Larissa Shamseer, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. Syst Rev 2015
11
Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: results from a phase 3 clinical trial (LOTUS).
Xuejun Zhu, Min Zheng, Michael Song, Yaung-Kaung Shen, Daphne Chan, Philippe O Szapary, Baoxi Wang. J Drugs Dermatol 2013
Xuejun Zhu, Min Zheng, Michael Song, Yaung-Kaung Shen, Daphne Chan, Philippe O Szapary, Baoxi Wang. J Drugs Dermatol 2013
11
Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial.
Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa. J Dermatol 2012
Atsuyuki Igarashi, Takeshi Kato, Mai Kato, Michael Song, Hidemi Nakagawa. J Dermatol 2012
11
Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana. Adv Ther 2017
Sandra Adsit, Enrique Rivas Zaldivar, Howard Sofen, Ignacio Dei-Cas, César Maldonado-García, Elkin O Peñaranda, Luís Puig, Xiangyi Meng, Todd Fox, Adriana Guana. Adv Ther 2017
11
Infliximab monotherapy for Chinese patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled multicenter trial.
Hai-Zhen Yang, Ke Wang, Hong-Zhong Jin, Tian-Wen Gao, Sheng-Xiang Xiao, Jin-Hua Xu, Bao-Xi Wang, Fu-Ren Zhang, Chun-Yang Li, Xiao-Ming Liu,[...]. Chin Med J (Engl) 2012
Hai-Zhen Yang, Ke Wang, Hong-Zhong Jin, Tian-Wen Gao, Sheng-Xiang Xiao, Jin-Hua Xu, Bao-Xi Wang, Fu-Ren Zhang, Chun-Yang Li, Xiao-Ming Liu,[...]. Chin Med J (Engl) 2012
11
Efficacy and safety of ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis: Subgroup analysis of a placebo-controlled, phase 3 study (UNCOVER-1).
Shinichi Imafuku, Hitoe Torisu-Itakura, Atsushi Nishikawa, Fangyi Zhao, Gregory S Cameron. J Dermatol 2017
Shinichi Imafuku, Hitoe Torisu-Itakura, Atsushi Nishikawa, Fangyi Zhao, Gregory S Cameron. J Dermatol 2017
11
Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study.
L Cai, J Gu, J Zheng, M Zheng, G Wang, L-Y Xi, F Hao, X-M Liu, Q-N Sun, Y Wang,[...]. J Eur Acad Dermatol Venereol 2017
L Cai, J Gu, J Zheng, M Zheng, G Wang, L-Y Xi, F Hao, X-M Liu, Q-N Sun, Y Wang,[...]. J Eur Acad Dermatol Venereol 2017
11
The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study.
JianZhong Zhang, Tsen-Fang Tsai, Min-Geol Lee, Min Zheng, Gang Wang, HongZhong Jin, Jun Gu, RuoYu Li, QuanZhong Liu, Jin Chen,[...]. J Dermatol Sci 2017
JianZhong Zhang, Tsen-Fang Tsai, Min-Geol Lee, Min Zheng, Gang Wang, HongZhong Jin, Jun Gu, RuoYu Li, QuanZhong Liu, Jin Chen,[...]. J Dermatol Sci 2017
11
Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study.
Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, Mamitaro Ohtsuki. J Dermatol 2010
Akihiko Asahina, Hidemi Nakagawa, Takafumi Etoh, Mamitaro Ohtsuki. J Dermatol 2010
11
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study.
F Valenzuela, C de la Cruz Fernandez, R L Galimberti, S Gürbüz, M McKean-Matthews, L Goncalves, R Romiti. Actas Dermosifiliogr 2017
F Valenzuela, C de la Cruz Fernandez, R L Galimberti, S Gürbüz, M McKean-Matthews, L Goncalves, R Romiti. Actas Dermosifiliogr 2017
25
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
Alan Menter, Stephen K Tyring, Kenneth Gordon, Alexa B Kimball, Craig L Leonardi, Richard G Langley, Bruce E Strober, Martin Kaul, Yihua Gu, Martin Okun,[...]. J Am Acad Dermatol 2008
11
Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study.
Hidemi Nakagawa, Hiroaki Niiro, Kenji Ootaki. J Dermatol Sci 2016
Hidemi Nakagawa, Hiroaki Niiro, Kenji Ootaki. J Dermatol Sci 2016
11
Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.
Masatoshi Abe, Chikako Nishigori, Hideshi Torii, Hironobu Ihn, Kei Ito, Makoto Nagaoka, Naoki Isogawa, Isao Kawaguchi, Yukiko Tomochika, Mihoko Kobayashi,[...]. J Dermatol 2017
Masatoshi Abe, Chikako Nishigori, Hideshi Torii, Hironobu Ihn, Kei Ito, Makoto Nagaoka, Naoki Isogawa, Isao Kawaguchi, Yukiko Tomochika, Mihoko Kobayashi,[...]. J Dermatol 2017
12
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
J-H Saurat, G Stingl, L Dubertret, K Papp, R G Langley, J-P Ortonne, K Unnebrink, M Kaul, A Camez. Br J Dermatol 2008
11
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.